Regeneron Pharmaceuticals Conducts Phase 1 Trial for Early Parkinson's Disease Treatment

Strategic Insights -

Regeneron Pharmaceuticals has launched an interventional clinical trial, Phase 1, aimed at evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of single ascending doses of intrathecally administered ALN-SNCA in participants with early Parkinson's disease. The trial, which is not yet open for recruiting, will involve 46 participants from the USA and will investigate whether the study drug, ALN-SNCA, can safely treat early Parkinson's disease, a disorder of the nervous system that affects movement. Parkinson's disease is caused by a gradual loss of nerve cells in the brain, particularly those affected by the harmful buildup of a protein called ð-synuclein.

Key Takeaways:

  • The trial aims to assess the safety and tolerability of ALN-SNCA in 46 participants with early Parkinson's disease.
  • The study will examine whether ALN-SNCA can lower the level of ð-synuclein protein in cerebrospinal fluid (CSF).
  • The trial will investigate the pharmacokinetics of ALN-SNCA in the blood, urine, and CSF.
  • Researchers will also explore whether ALN-SNCA can slow down the progression of Parkinson's disease symptoms.
  • The trial is focused on understanding the study drug (ALN-SNCA) and Parkinson's disease, including the relationship between ð-synuclein and the progression of Parkinson's disease.
  • The study is being conducted to determine the feasibility of future studies and the potential side effects of ALN-SNCA.

Statistics:

  • 46 participants will be involved in the trial.
  • The trial will be conducted in the USA.
  • The study aims to assess the safety and tolerability of ALN-SNCA in participants with early Parkinson's disease.

Sources:

1. ClinicalTrials.gov - "Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of Intrathecally Administered ALN-SNCA in Participants With Early Parkinson's Disease."